Rama Elluru

Rama G. Elluru is currently a Senior Director at the Special Competitive Studies Project (SCSP), a non-profit, funded by Eric and Wendy Schmidt and established to make recommendations to strengthen America’s long-term competitiveness for a future where artificial intelligence (AI) and other emerging technologies reshape our national security, economy, and society.  Previous to the SCSP, she was a Director at the National Security Commission on Artificial Intelligence (NSCAI), an independent Commission established by Congress to consider the methods and means to advance the development of AI, ML, and associated technologies to address the national security and defense needs of the United States.  She was detailed to the NSCAI from the United States Patent and Trademark Office (USPTO), where she served as an Administrative Patent Judge on the Patent Trial and Appeal.  Before joining the USPTO, Rama practiced IP law for 20 years, particularly in analyzing and litigating E.E. and bio-pharma patents. She graduated from Trinity University with a B.S. in Computer Science/Philosophy and obtained a J.D. from the Washington and Lee School of Law. After law school, she received a M.S. in Biochemistry/Molecular Biology from Georgetown University.

When AI Helps Generate Inventions, Who Is the Inventor?

By Andrei Iancu and Rama Elluru This commentary from the CSIS-SCSP Task Force on IP in the AI Era was originally published in the Special Competitive Studies Project’s Substack on February 15, 2024. With roots in the U.S. constitution, patent rights provide an exclusive property right in new inventions like drugs,
Read More

Standard Essential Patents and European Economic Security

By Kirti Gupta and Chris Borges On April 27, 2023, the European Commission published a draft proposal on standard essential patents (SEPs) seeking to address the perceived lack of transparency and predictability in the licensing of SEPs. The commission proposes the creation of a competence center within the European Union Intellectual
Read More

Proposed Federal Use of March-in Rights Would Weaken American Innovation

By Sujai Shivakumar and Thomas Howell   The Biden administration is considering exercising something called “march-in rights” as a policy prescription to curb drug prices. But as with any prescription, there is a need to weigh efficacy against the side-effects. In this case, there is evidence that the vast majority of
Read More